BMO Capital downgraded Tetraphase Pharmaceuticals (NASDAQ: TTPH) from Outperform to Market Perform with a price target of $2.75 (from $24.00).Analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst PT Change Downgrades Hot Downgrades

Tetraphase Pharmaceuticals (TTPH) PT Lowered to $6 at H.C. WainwrightFebruary 14, 2018 7:16 AM Tetraphase Pharmaceuticals (TTPH) PT Lowered to $6 at Stifel; Path Forward Complicated, But Still ThereFebruary 14, 2018 6:28 AM Tetraphase Pharmaceuticals (TTPH) PT Lowered to $8 at Piper JaffrayFebruary 14, 2018 6:15 AM